Combined BRAF (vemurafenib) and DUB inhibition effectively suppressed BRAF mutant melanoma in vitro colony growth (2D and 3D) and in vivo tumor growth, suggesting that combining these agents can block adaptive resistance mechanisms such as SOX2 induction. Here, SOX2 is linked to neoplasm.